Cargando…
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Advances in the understanding of cancer immunotherapy and the development of multiple checkpoint inhibitors have dramatically changed the current landscape of cancer treatment. Recent large-scale phase III trials (e.g. PHOCUS, OPTiM) are establishing use of oncolytic viruses as another tool in the c...
Autores principales: | LaRocca, Christopher J., Warner, Susanne G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234197/ https://www.ncbi.nlm.nih.gov/pubmed/30426287 http://dx.doi.org/10.1186/s40169-018-0214-5 |
Ejemplares similares
-
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
por: Sivanandam, Venkatesh, et al.
Publicado: (2019) -
A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer
por: LaRocca, Christopher J., et al.
Publicado: (2018) -
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020) -
Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
por: Friedman, Avner, et al.
Publicado: (2018) -
Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts
por: Huang, Jing Li, et al.
Publicado: (2016)